---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42047751.md"
description: "$WUXI APPTEC(02359.HK) rose over five percentage points, $AKESO(09926.HK) rose over four percentage points. Hong Kong-listed innovative drug stocks and CXOs are strengthening together, driven by expectations around AI drug discovery and overseas expansion. $Eli Lilly(LLY.US), on the other hand, dipped slightly. The logic for large pharmaceutical companies is different from that of small-cap innovative drug stocks; they are more weighed down by competition in weight-loss drugs and valuation digestion. Both are in the pharmaceutical sector, but Hong Kong-listed innovative drug stocks are rebounding, while US-listed large pharma companies are taking a breather. Given this US-HK divergence, should we follow the current momentum in Hong Kong stocks, or wait for large pharma valuations to come down for a more stable entry?"
datetime: "2026-06-22T09:26:49.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42047751.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42047751.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42047751.md)
author: "[Dimoo](https://longbridge.com/en/profiles/26968366.md)"
---

# $WUXI APPTEC(02359.HK) rose over five percentage p…


### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)